1 Functional Foods Forum, Faculty of Medicine, University of Turku, 20014 Turku, Finland;
2 Department of Food Sciences and Technology, University of Natural Resources and Life Science Vienna, 1190 Vienna, Austria;
Benef Microbes. 2016 Sep;7(4):571-84. doi: 10.3920/BM2016.0009. Epub 2016 Jun 13.
Akkermansia muciniphila is an intestinal anaerobe which has been proposed as a new functional microbe with probiotic properties. However, the species is not included in the European Union qualified presumption of safety (QPS) list and has not yet been assessed. Moreover, products containing A. muciniphila are not on the market and are thus controlled by the Novel Foods Regulation, which requires extensive safety assessment. This review addresses the safety aspects of the use of A. muciniphila based on published information on its functions in humans and predictions based on its activity in model animals. Further, comprehensive studies related to A. muciniphila and its safety properties have gradually appeared and are summarised here. Many of the criteria required for novel food safety assessment in Europe can thus be fulfilled. However, studies focusing on the toxicological properties of A. muciniphila, including long-term and reproduction studies, have not so far been reported and are discussed in the light of the observation that most, if not all, healthy subjects are known to carry this intestinal anaerobe. As this also applies to other beneficial bacteria found in the human intestinal tract, the A. muciniphila case can be seen as a model for the comprehensive safety evaluations required by the European authorities.
黏蛋白阿克曼菌是一种肠道厌氧菌,被提议作为具有益生菌特性的新型功能微生物。然而,该物种未被列入欧盟合格推定安全(QPS)清单,尚未进行评估。此外,含有黏蛋白阿克曼菌的产品尚未上市,因此受到新型食品法规的控制,该法规要求进行广泛的安全评估。本综述基于黏蛋白阿克曼菌在人类中的功能的已发表信息以及基于其在模型动物中的活性的预测,讨论了使用黏蛋白阿克曼菌的安全性方面。此外,与黏蛋白阿克曼菌及其安全性特性相关的综合研究逐渐出现,本文对此进行了总结。因此,欧洲新型食品安全评估所需的许多标准都可以得到满足。然而,目前尚未报道针对黏蛋白阿克曼菌的毒理学特性(包括长期和生殖研究)的研究,并且鉴于观察到大多数(如果不是全部)健康受试者都携带这种肠道厌氧菌,因此对此进行了讨论。由于这也适用于人类肠道中发现的其他有益细菌,因此黏蛋白阿克曼菌案例可以被视为欧洲当局要求的全面安全评估的模型。